314 related articles for article (PubMed ID: 27170515)
21. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
[TBL] [Abstract][Full Text] [Related]
22. Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
Kats A; Norgård M; Wondimu Z; Koro C; Concha Quezada H; Andersson G; Yucel-Lindberg T
J Cell Mol Med; 2016 Jun; 20(6):1128-38. PubMed ID: 26987561
[TBL] [Abstract][Full Text] [Related]
23. Protocatechuic acid inhibits osteoclast differentiation and stimulates apoptosis in mature osteoclasts.
Wu YX; Wu TY; Xu BB; Xu XY; Chen HG; Li XY; Wang G
Biomed Pharmacother; 2016 Aug; 82():399-405. PubMed ID: 27470378
[TBL] [Abstract][Full Text] [Related]
24. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Aggarwal BB
Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
[TBL] [Abstract][Full Text] [Related]
25. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis.
Kim MH; Ryu SY; Bae MA; Choi JS; Min YK; Kim SH
Food Chem Toxicol; 2008 Nov; 46(11):3375-82. PubMed ID: 18786594
[TBL] [Abstract][Full Text] [Related]
26. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-κB and MAPK pathways.
Deepak V; Kasonga A; Kruger MC; Coetzee M
Connect Tissue Res; 2015 Jun; 56(3):195-203. PubMed ID: 25405641
[TBL] [Abstract][Full Text] [Related]
28. Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells.
Ko SY
Arch Oral Biol; 2012 Dec; 57(12):1623-32. PubMed ID: 22795564
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
30. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
[TBL] [Abstract][Full Text] [Related]
31. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
32. Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL.
Suda K; Woo JT; Takami M; Sexton PM; Nagai K
J Cell Physiol; 2002 Jan; 190(1):101-8. PubMed ID: 11807816
[TBL] [Abstract][Full Text] [Related]
33. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
[TBL] [Abstract][Full Text] [Related]
34. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
35. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
37. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
38. Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways.
Chen F; Xie L; Kang R; Deng R; Xi Z; Sun D; Zhu J; Wang L
Biomed Pharmacother; 2018 Apr; 100():142-146. PubMed ID: 29428661
[TBL] [Abstract][Full Text] [Related]
39. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid.
Rahman MM; Bhattacharya A; Fernandes G
J Cell Physiol; 2008 Jan; 214(1):201-9. PubMed ID: 17929247
[TBL] [Abstract][Full Text] [Related]
40. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells.
Abe K; Yoshimura Y; Deyama Y; Kikuiri T; Hasegawa T; Tei K; Shinoda H; Suzuki K; Kitagawa Y
Int J Mol Med; 2012 Jun; 29(6):1007-15. PubMed ID: 22447156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
